Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease

Published:2023-02 Issue:2 Volume:8 Page:179-191
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Targher Giovanni,Mantovani Alessandro,Byrne Christopher D

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference88 articles.

1. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality;Karlsen;Lancet,2022

2. Non-alcoholic fatty liver disease;Powell;Lancet,2021

3. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world;Henry;Aliment Pharmacol Ther,2022

4. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis;Riazi;Lancet Gastroenterol Hepatol,2022

5. Management of non-alcoholic fatty liver disease;Petroni;BMJ,2021

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoglycemic peptide preparation from Bacillus subtilis fermented with Pyropia: Identification, molecular docking, and in vivo confirmation;Food Chemistry;2025-01

2. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease;Gut;2024-09-06

3. Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus;Journal of the Pakistan Medical Association;2024-08-23

4. Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review;Cureus;2024-08-17

5. Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study;Diabetes Therapy;2024-08-07